|
Jan 17
|
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
|
|
Nov 30
|
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
|
|
Aug 10
|
LTRN: 2Q:23 Quarterly Update
|
|
Aug 9
|
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
|